Management of nonalcoholic steatohepatitis: An analytic review

Journal of Clinical Gastroenterology

Volumn 35, Issue 3, 2002, Pages 253-261

  Agrawal, Sanjay ^a   Bonkovsky, Herbert L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Liver; Management; Nonalcoholic steatohepatitis

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; BETAINE; BEZAFIBRATE; CHOLINE; CLOFIBRATE; CYTOKINE; GEMFIBROZIL; IRON; LEPTIN; LIVER PROTECTIVE AGENT; METFORMIN; SILYMARIN; TAMOXIFEN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; FATTY LIVER; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; JEJUNOILEAL BYPASS; LIVER PROTECTION; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PHLEBOTOMY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; TOXIC HEPATITIS; VITAMIN DEFICIENCY; WEIGHT REDUCTION;

DIABETES MELLITUS; FATTY LIVER; HEPATITIS; HUMANS; HYPERINSULINISM; IRON; LEPTIN; LIVER TRANSPLANTATION; RISK FACTORS; SILYMARIN; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; URSODEOXYCHOLIC ACID; VITAMIN E;

EID: 0036720313     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200209000-00011     Document Type: Review

References (95)

1. Nonalcoholic steatohepatilis: Mayo Clinic experiences with a hitherto unnamed disease
2. Non-alcoholic fatty liver disease: A review
3. Nonalcoholic fatty liver disease: The most common cause of abnormal liver enzymes in the U.S. population
4. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
5. Nonalcoholic steatohepatitis
6. Nonalcoholic steatohepatiits
7. Nonalcoholic steatohepatitis
8. Nonalcoholic steatohepatitis
9. Nonalcoholic steatohepatitis
10. Nonalcoholic steatohepatitis
11. Update on nonalcoholic fatty liver disease
12. Metabolic and nutritional considerations in nonalcoholic fatty liver
13. Cytokines in alcoholic and nonalcoholic steatohepatitis
14. Nonalcoholic fatty liver disease: A spectrum of clinical and pathologic severity
15. Nonalcoholic steatohepatitis: An expanded clinical entity
16. Steatohepatitis: A tale of "two hits?"
17. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
18. Insulin resistance and nonalcoholic steatohepatitis: Fat or fiction
19. Nonalcoholic steatohepatitis in obesity: A reversible condition
20. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study
21. Persistent hyperaminotransferasemia resolving after weight reduction in obese children
22. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
23. Fasting in obesity: Another cause of liver injury with alcoholic hyaline?
24. Liver morphology and function tests in obesity and during starvation
25. Prevention of type 2 diabetes mellitus by changes in life style among subjects with impaired glucose tolerance
26. Changing habits to delay diabetes
27. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
28. Hepatic failure in a patient taking rosiglitazone
29. Hepatocellular injury in a patient receiving rosiglitazone
30. Metformin treatment in patients with nonalcoholic steatohepatitis [abstract]
31. Metformin reverses fatty liver disease in obese, leptin deficient mice
32. Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans
33. Serum leptin levels in patients with nonalcoholic steatohepatitis
34. Leptin, obesity, and liver disease
35. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
36. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
37. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
38. Cytoprotection with ursodeoxycholic acid: Effect in chronic non-cholestatic and cholestatic liver disease
39. Two cases from the spectrum of nonalcoholic steatohepatitis
40. Ursodeoxycholic acid in the treatment on nonalcoholic steatohepatitis: Results of a prospective clinical controlled trial
41. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis
42. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children
43. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis
44. Increased hepatic iron concentration in NASH is associated with increased fibrosis
45. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
46. Non-alcoholic steatohepatitis with iron: Part of insulin resistance-associated hepatic iron overload?
47. Hepatic iron and nonalcoholic fatty liver disease
48. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
49. Insulin-resistance associated iron overload
50. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis
51. Clinical spectrum of hepatic disease in hemochromatosis
52. Iron and chronic viral hepatitis
53. A pilot randomized, controlled trial of the effect of iron depletion on long term response to alpha-interferon in patients with chronic hepatitis C
54. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial
55. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who had previously not responded to interferon: A multicenter, prospective, randomized, controlled trial
56. Iron and NASH
57. Phlebotomy reduces transaminase levels in patients with chronic non-alcoholic steatohepatitis
58. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH)
59. Venesection therapy of insulin-resistance-associated iron overload
60. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of non-alcoholic fatty liver disease
61. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents
62. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
63. Long term (12 months) treatment with and anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need, and malondialdehyde levels in cirrhotic diabetic patients
64. Treatment of non-alcoholic steatohepatitis with N-acetylcysteine
65. Improvement of liver function tests by administration of L-carnitine to a carnitine-deficient patient receiving home parenteral nutrition: A case report
66. L-carnitine effect of intravenous administration on fuel homeostasis in normal subjects and home-parenteral-nutrition patients with low plasma carnitine concentration
67. L-carnitine therapy in home parenteral nutrition patients with abnormal liver tests and low plasma carnitine concentrations
68. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients
69. Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation
70. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon
71. Increased circulating level of dilinoleylphosphatidylcholine is associated with protection against alcohol induced oxidative stress and liver fibrosis in man
72. Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration
73. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study
74. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat
75. A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements
76. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin-6
77. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
78. Molecular pathogenesis of cholestasis
79. Initiation of liver growth by tumor necrosis factor: Deficient liver regeneration in mice lacking type I tumor necrosis factor receptor
80. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy
81. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice
82. Interferon gamma receptor deficient mice are resistant to endotoxic shock
83. A pivotal role of IL-12 in Th1-dependent mouse liver injury
84. IL-18-deficient mice are resistant to endotoxin induced liver injury but highly susceptible to endotoxin shock
85. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis a double-blind, placebo-controlled trial
86. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
87. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes
88. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis
89. Clinical and metabolic studies following bowel by-passing for obesity
90. Cryptogenic cirrhosis and recurrence of non-alcoholic fatty liver disease after liver transplantation
91. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation
92. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient
93. Recurrence of nonalcoholic steatohepatitis following liver transplantation
94. Liver transplantation for nonalcoholic steatohepatitis [abstract]
95. Nonalcoholic steatohepatitis: A proposal for grading and staging the histologic lesions